Anixa Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 16, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Market Cap	113	136	113	98	173	143
Market Cap Growth	8.61%	20.99%	14.50%	-43.15%	20.77%	186.96%
Enterprise Value	99.45	120.17	91.89	73.78	142.81	107.2
Last Close Price	3.32	4.13	3.50	3.16	5.60	4.77
Forward PE	-	4.85	4.85	4.85	4.27	4.27
PS Ratio	-	-	-	468.66	-	279.97
PB Ratio	7.78	8.99	5.64	4.04	5.96	4.04
P/TBV Ratio	7.58	8.84	5.58	4.02	5.86	3.85
EV/Sales Ratio	-	-	-	351.35	-	209.38
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.01	0.01
Net Debt / Equity Ratio	-0.93	-0.99	-0.98	-0.97	-1.01	-1.00
Net Debt / EBITDA Ratio	1.27	1.28	1.43	2.16	2.13	2.71
Net Debt / FCF Ratio	1.90	2.09	2.69	3.81	4.54	7.18
Asset Turnover	-	0	0	0.01	0	0.02
Quick Ratio	9.16	7.71	8.04	11.89	14.60	28.13
Current Ratio	9.79	8.08	8.54	12.50	14.83	28.35
Return on Equity (ROE)	-74.50%	-67.17%	-60.10%	-38.51%	-43.74%	-61.02%
Return on Assets (ROA)	-68.99%	-62.12%	-58.71%	-39.37%	-41.62%	-57.48%
Return on Capital Employed (ROCE)	-77.70%	-70.48%	-64.96%	-42.46%	-43.80%	-60.74%
Buyback Yield / Dilution	-2.80%	-1.74%	-2.96%	-2.00%	-6.28%	-28.57%
Total Shareholder Return	-2.80%	-1.74%	-2.96%	-2.00%	-6.28%	-28.57%

SEC Filings: 10-K · 10-Q